FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 天安卓健有限公司 呈交日期： 2025年10月2日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 00383 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的 ...

| | | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 天安卓健有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00383 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,000,000 | 本月底法定/註冊股本總額： HKD 300,000, ...

Core Viewpoint - Tianan Health (00383.HK) announced a share buyback on September 29, spending HKD 22,500 to repurchase 25,000 shares at a price of HKD 0.90 per share [1] Summary by Relevant Categories - **Company Actions** - The company executed a buyback of 25,000 shares at a total cost of HKD 22,500, indicating a strategic move to enhance shareholder value [1] - The repurchase price per share was set at HKD 0.90, reflecting the company's valuation of its own shares [1] - **Market Implications** - This buyback may signal confidence in the company's future performance and could potentially influence market perception positively [1] - The action could also impact the stock's liquidity and overall market dynamics for Tianan Health [1]

Core Viewpoint - Tianan Health (00383) announced a share buyback of 25,000 shares at a cost of HKD 22.5 million, scheduled for September 29, 2025 [1] Summary by Category - **Company Actions** - The company is engaging in a share repurchase program, indicating confidence in its own stock value [1] - The total expenditure for the buyback is HKD 22.5 million [1] - **Financial Implications** - The buyback of 25,000 shares suggests a strategic move to enhance shareholder value [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 於下列日期結束時的結存 (註5及6) | | 2025年9月29日 | 1,082,755,457 | | 0 | | 1,082,755,457 | | --- | --- | --- | --- | --- | --- | --- | --- | | B. 贖回/購回股份 (擬註銷但截至期終結存日期尚未註銷) (註5及6) | | | | | | | | | 已購回以作註銷但尚未註銷之股份 | 1). | | 95,000 | 0.0088 % | HKD | 0.9 | | | 變動日期 | 2025年9月23日 | | | | | | | | 已購回以作註銷但尚未註銷之股份 | 2). | | 25,000 | 0.0023 % | HKD | 0.9 | | | 2025年9月29日 | 變動日期 | | | | | | | 第 2 頁 共 7 頁 v 1.3.0 FF305 表格類別： 股票 狀態： 新提交 公司名稱： 天安卓健有限公司 呈交日期： 2025年9月29日 如上市發行人的已 ...

Summary of Key Points Core Viewpoint - Multiple companies, including Tencent Holdings and Anta Sports, conducted share buybacks on September 23, 2025, with Tencent leading in terms of buyback amount and quantity [1][2]. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 867,000 shares for a total of 550 million [2]. - Anta Sports (02020) repurchased 2.12 million shares for a total of 200 million [2]. - Hang Seng Bank (00011) repurchased 200,000 shares for a total of 23.57 million [2]. - China Petroleum & Chemical Corporation (00386) repurchased 5.51 million shares for a total of 22.44 million [2]. - Stone Four Pharmaceutical Group (02005) repurchased 5 million shares for a total of 14.67 million [2]. Group 2: Cumulative Buyback Data - Tencent's cumulative buyback for the year reached 61.59 million shares, accounting for 0.670% of its total share capital [2]. - Anta Sports' cumulative buyback for the year reached 4.24 million shares, accounting for 0.151% of its total share capital [2]. - China Hongqiao Group (01378) had a cumulative buyback of 15.2 million shares, accounting for 1.620% of its total share capital [2]. - Coolpad Group (02369) had a significant cumulative buyback of 27.25 million shares, accounting for 6.653% of its total share capital [2].

Group 1 - The company Tianan Health (00383.HK) announced a share buyback on September 23, spending HKD 86,000 to repurchase 95,000 shares [1]

Group 1 - The company Tianan Health (00383) announced a share buyback plan, committing to repurchase 95,000 shares at a total cost of HKD 85.5 million [1]

FF305 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 00383 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年9月15日 | | 1,082,840,457 | | 0 | | 1,082,840,457 | | 1). 其他 (請註明) | | | | % | | | | | 見B部 | | | | | | | | | 變動日期 2025年9月23日 | | | | | | | | | ...

[Supplementary Announcement Overview](index=1&type=section&id=Supplementary%20Announcement%20Overview) This section provides an overview of the supplementary announcement, detailing its purpose and the context of the additional information provided [Purpose and Background of Announcement](index=1&type=section&id=Purpose%20and%20Background%20of%20Announcement) This announcement supplements detailed information regarding the share option scheme in Tian An Zhuo Jian Co., Ltd.'s 2024 annual report and 2025 interim report - This announcement serves as a supplement to Tian An Zhuo Jian Co., Ltd.'s 2024 annual report and 2025 interim report[2](index=2&type=chunk)[3](index=3&type=chunk) - The supplementary information primarily addresses the 'Note 42. Share Option Scheme' section in the 'Notes to the Consolidated Financial Statements' of the annual report and 'Note 22. Share Option Scheme' section in the 'Notes to the Condensed Consolidated Financial Statements' of the interim report[3](index=3&type=chunk) [Supplementary Details on Share Option Scheme](index=1&type=section&id=Supplementary%20Details%20on%20Share%20Option%20Scheme) This section provides specific details on the share option scheme, including authorized shares and their proportion to issued shares [Authorized and Issuable Shares under the Scheme](index=1&type=section&id=Authorized%20and%20Issuable%20Shares%20under%20the%20Scheme) As of various dates in 2024 and 2025, the number of share options authorized for grant and the total shares available for issue under the scheme remained constant at 72,400,363 shares Authorized and Issuable Shares under Share Option Scheme | Metric | Quantity (Shares) | | :--- | :--- | | Options authorized for grant as of January 1, 2024 | 72,400,363 | | Options authorized for grant as of December 31, 2024 | 72,400,363 | | Options authorized for grant as of January 1, 2025 | 72,400,363 | | Options authorized for grant as of June 30, 2025 | 72,400,363 | | Total shares available for issue under the scheme | 72,400,363 | [Proportion of Share Options to Issued Shares](index=1&type=section&id=Proportion%20of%20Share%20Options%20to%20Issued%20Shares) As of the annual and interim report dates, the total shares available for issue under the share option scheme represented approximately 6.7% of the total issued shares Proportion of Share Options to Issued Shares | Date | Total Issued Shares (Excluding Treasury Shares) | Proportion of Share Options to Issued Shares | | :--- | :--- | :--- | | Annual Report Date (March 10, 2025) | 1,084,815,457 Shares | Approximately 6.7% | | Interim Report Date (August 1, 2025) | 1,082,850,457 Shares | Approximately 6.7% | [Corporate Governance Information](index=1&type=section&id=Corporate%20Governance%20Information) This section outlines the composition of the Board of Directors as of a specific date [Composition of the Board of Directors](index=1&type=section&id=Composition%20of%20the%20Board%20of%20Directors) As of September 17, 2025, the Board of Directors consists of three executive, four non-executive, and four independent non-executive directors - As of September 17, 2025, the Board of Directors includes: * Executive Directors: Mr. Jiang Muxian, Mr. Guo Meibao, Mr. Zhou Haiying * Non-Executive Directors: Mr. Li Chenghui (Chairman), Mr. Wang Dajun, Mr. Gao Zhaoyuan, Ms. Zhang Yuanyuan * Independent Non-Executive Directors: Dr. Xia Xiaoning, Dr. Wang Yongquan, Ms. Yang Lichen, Mr. Cao Dan[5](index=5&type=chunk)